name: interpreting-echocardiograms language: en description: Structures echocardiographic interpretation with chamber measurements, valve assessment, and functional parameters. Use when reading echo reports, documenting cardiac function, or evaluating valve disease. tags:
- analysis
- cardiology
metadata:
author: casemark
practice_areas:
- Cardiology
- Interventional Cardiology
- Electrophysiology document_types:
- Interpretation Report skill_modes:
- Analysis
- Interpretation
Interpreting Echocardiograms
Structures echocardiographic interpretation with chamber measurements, valve assessment, and functional parameters.
Why This Skill Exists
Echocardiography is the most frequently ordered cardiac imaging study, with over 7 million performed annually in the US alone. Interpretation quality varies widely, and missed findings — an underestimated mitral regurgitation severity, an overlooked diastolic dysfunction pattern, or an unrecognized wall motion abnormality — directly alter surgical timing, device eligibility, and medical therapy decisions. The ASE (American Society of Echocardiography) guidelines mandate structured, quantitative reporting to reduce interpretive variability.
This skill enforces ASE-standard chamber quantification, valve assessment grading, and hemodynamic parameter documentation, ensuring every report is complete, reproducible, and actionable.
Checkpoint A: Pre-Draft Intake (Mandatory)
- What is the clinical indication for the echocardiogram? (default: "Evaluate cardiac structure and function")
- What is the study type — transthoracic (TTE), transesophageal (TEE), stress echo, or contrast echo? (default: "TTE")
- Is a prior echocardiogram available for comparison? (default: "No prior study available")
- What is the patient's body surface area (BSA)? (default: "Not provided — will index to available BSA or flag")
- Are there specific clinical questions — valve disease severity, LV function post-MI, pre-surgical evaluation, source of embolism? (default: "Comprehensive assessment")
- Does the patient have a prosthetic valve, cardiac device, or prior cardiac surgery? (default: "None known")
- What is the image quality — adequate, limited, or technically difficult? (default: "To be determined on review")
Documents to Request
- Complete echocardiogram study (DICOM or structured report)
- Prior echocardiogram for comparison
- Patient height and weight for BSA calculation
- Recent ECG (for rhythm context during echo interpretation)
- Clinical referral note with specific question
- Relevant labs: BNP/NT-proBNP, troponin if applicable
- Cardiac catheterization data if available (for hemodynamic correlation)
Step 1: LV Size and Systolic Function Assessment
LV Chamber Quantification (ASE Reference Ranges):
| Parameter | Normal Male | Normal Female | Mild | Moderate | Severe |
|---|---|---|---|---|---|
| LVIDd (cm) | 4.2–5.8 | 3.8–5.2 | 5.9–6.3 / 5.3–5.6 | 6.4–6.8 / 5.7–6.1 | ≥ 6.9 / ≥ 6.2 |
| LVEF (%) | ≥ 52 | ≥ 54 | 41–51 / 41–53 | 30–40 | < 30 |
| LV mass index (g/m²) | ≤ 115 | ≤ 95 | 116–131 / 96–108 | 132–148 / 109–121 | ≥ 149 / ≥ 122 |
LVEF Assessment Methods (in order of preference):
- Biplane Simpson's method of discs — standard for 2D
- 3D volumetric assessment — most accurate when image quality permits
- Visual estimation — acceptable for experienced readers, but quantitative method must be documented
Wall Motion Analysis:
- Score each of the 17 AHA segments: 1 = normal, 2 = hypokinetic, 3 = akinetic, 4 = dyskinetic, 5 = aneurysmal
- Wall motion score index (WMSI) = sum of scores / number of segments visualized
- WMSI > 1.0 indicates regional dysfunction; map to coronary territories
Global Longitudinal Strain (GLS):
- Normal: −18% to −22% (more negative = better function)
- Abnormal: > −16% (less negative)
- GLS can detect subclinical LV dysfunction before LVEF declines — critical for cardiotoxicity screening
Step 2: Diastolic Function Assessment
ASE/EACVI 2016 Diastolic Grading Algorithm:
| Parameter | Normal | Grade I | Grade II | Grade III |
|---|---|---|---|---|
| E/A ratio | 0.8–2.0 | < 0.8 | 0.8–2.0 | > 2.0 |
| E/e' (average) | < 10 | < 10 | 10–14 | > 14 |
| TR velocity (m/s) | < 2.8 | < 2.8 | > 2.8 | > 2.8 |
| LA volume index (mL/m²) | < 34 | < 34 | ≥ 34 | ≥ 34 |
Key Rules:
- If LVEF is normal: check average E/e', TR velocity, and LA volume index. If ≥ 2 of 3 are abnormal → diastolic dysfunction present; then grade using E/A ratio
- If E/A < 0.8 and E/e' < 10: Grade I (impaired relaxation)
- If E/A 0.8–2.0 with ≥ 2 abnormal parameters: Grade II (pseudonormal)
- If E/A > 2.0, deceleration time < 160 ms: Grade III (restrictive)
Step 3: Valve Assessment
Aortic Stenosis Severity (ACC/AHA 2020):
| Parameter | Mild | Moderate | Severe |
|---|---|---|---|
| Peak velocity (m/s) | 2.0–2.9 | 3.0–3.9 | ≥ 4.0 |
| Mean gradient (mmHg) | < 20 | 20–39 | ≥ 40 |
| AVA (cm²) | > 1.5 | 1.0–1.5 | < 1.0 |
| AVAi (cm²/m²) | — | — | < 0.6 |
Mitral Regurgitation Severity (ASE Integrated Approach):
| Parameter | Mild | Moderate | Severe |
|---|---|---|---|
| Vena contracta (cm) | < 0.3 | 0.3–0.69 | ≥ 0.7 |
| EROA (cm²) | < 0.2 | 0.2–0.39 | ≥ 0.4 |
| Regurgitant volume (mL) | < 30 | 30–59 | ≥ 60 |
| Regurgitant fraction (%) | < 30 | 30–49 | ≥ 50 |
For each valve, document: morphology, leaflet mobility, calcification, stenosis severity, regurgitation severity, and mechanism of dysfunction.
Step 4: Right Heart and Hemodynamic Assessment
RV Assessment:
- TAPSE (tricuspid annular plane systolic excursion): Normal ≥ 17 mm
- RV S' (tissue Doppler at tricuspid annulus): Normal ≥ 9.5 cm/s
- RV fractional area change: Normal ≥ 35%
- RV free-wall longitudinal strain: Normal < −20%
Pulmonary Artery Pressure Estimation:
- RVSP = 4 × (TR velocity)² + RAP
- RAP estimation by IVC: < 2.1 cm with > 50% collapse = 3 mmHg; > 2.1 cm with < 50% collapse = 15 mmHg
Pericardial Assessment:
- Effusion size: trivial (< 0.5 cm), small (0.5–1 cm), moderate (1–2 cm), large (> 2 cm)
- Tamponade physiology: RA diastolic collapse, RV diastolic collapse, respiratory variation > 25% mitral inflow
Step 5: Structured Report Synthesis
Compile findings into a structured report following ASE reporting format:
- Study indication and clinical context
- LV size, wall thickness, systolic function (LVEF, GLS if obtained)
- Regional wall motion abnormalities (if any, mapped to coronary territories)
- Diastolic function grade with supporting parameters
- Each valve: morphology, stenosis grade, regurgitation grade
- RV size and function
- PA pressure estimate
- Pericardium
- Aortic root dimensions
- Comparison with prior study
- Summary impression with clinical recommendations
Checkpoint B: Post-Draft Alignment (Mandatory)
- Is LVEF reported quantitatively with the method used?
- Is diastolic function formally graded using the ASE 2016 algorithm?
- Are all four valves assessed for both stenosis and regurgitation?
- Is RV function quantified (not just "qualitatively normal")?
- Does the summary impression directly address the clinical question?
Quality Audit
- LV dimensions indexed to BSA where appropriate
- LVEF reported with method (Simpson biplane, 3D, visual)
- Wall motion assessed by 17-segment model or abnormalities listed by segment
- Diastolic function graded I–III with at least 3 supporting parameters
- All four valves assessed and severity graded
- Aortic stenosis evaluated with velocity, gradient, and valve area (discordance addressed if present)
- Mitral regurgitation assessed with at least two quantitative parameters
- RV size and function quantified (TAPSE minimum)
- PA pressure estimated or "TR insufficient for estimate" documented
- Pericardial space assessed
- Aortic root measured at sinuses of Valsalva
- Prior study comparison made or absence documented
- Image quality limitations acknowledged
- Clinical correlation and recommendations provided
Guidelines
- Always index chamber dimensions and volumes to BSA — absolute measurements alone are insufficient for clinical grading.
- When aortic stenosis severity parameters are discordant (e.g., low gradient with small valve area), document the discrepancy and consider low-flow states, measurement error, or dobutamine stress echo.
- For mitral regurgitation, never rely on a single parameter — use the ASE integrated approach with at least two quantitative measures.
- GLS should be included when available, especially for oncology patients on cardiotoxic therapy (anthracyclines, trastuzumab) and pre-operative assessments.
- Diastolic function cannot be reliably graded in atrial fibrillation using standard E/A ratios — use E/e' and LA volume index as primary parameters.
- Always note whether contrast was used and whether it changed the LVEF assessment.
- Report any incidental findings (pleural effusions, ascites, lung consolidation) visible on the echo study.